Abstract
Introduction
Primary hyperparathyroidism is associated with a cluster of cardiovascular manifestations, including hypertension, leading to increased cardiovascular risk.
Purpose
The aim of our study was to investigate the ambulatory blood pressure monitoring-derived short-term blood pressure variability in patients with primary hyperparathyroidism, in comparison with patients with essential hypertension and normotensive controls.
Methods
Twenty-five patients with primary hyperparathyroidism (7 normotensive,18 hypertensive) underwent ambulatory blood pressure monitoring at diagnosis, and fifteen out of them were re-evaluated after parathyroidectomy. Short-term-blood pressure variability was derived from ambulatory blood pressure monitoring and calculated as the following: 1) Standard Deviation of 24-h, day-time and night-time-BP; 2) the average of day-time and night-time-Standard Deviation, weighted for the duration of the day and night periods (24-h “weighted” Standard Deviation of BP); 3) average real variability, i.e., the average of the absolute differences between all consecutive BP measurements.
Results
Baseline data of normotensive and essential hypertension patients were matched for age, sex, BMI and 24-h ambulatory blood pressure monitoring values with normotensive and hypertensive-primary hyperparathyroidism patients, respectively. Normotensive-primary hyperparathyroidism patients showed a 24-h weighted Standard Deviation (P < 0.01) and average real variability (P < 0.05) of systolic blood pressure higher than that of 12 normotensive controls. 24-h average real variability of systolic BP, as well as serum calcium and parathyroid hormone levels, were reduced in operated patients (P < 0.001). A positive correlation of serum calcium and parathyroid hormone with 24-h-average real variability of systolic BP was observed in the entire primary hyperparathyroidism patients group (P = 0.04, P = 0.02; respectively).
Conclusion
Systolic blood pressure variability is increased in normotensive patients with primary hyperparathyroidism and is reduced by parathyroidectomy, and may potentially represent an additional cardiovascular risk factor in this disease.
Similar content being viewed by others
References
C. Marcocci, F. Cetani, Clinical practice. Primary hyperparathyroidism. N. Engl. J. Med. 365, 2389–2397 (2011)
P. Andersson, E. Rydberg, R. Willenheimer, Primary hyperparathyroidism and heart disease-a review. Eur. Heart J. 25, 1776–1787 (2004)
P. Luigi, F.M. Chiara, Z. Laura, M. Cristiano, C. Giuseppina, C. Luciano, P. Giuseppe, C. Sabrina, S. Susanna, C. Antonio, C. Giuseppe, T. Giorgio de, L. Claudio, Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. Int. J. Endocrinol. 2012, 408295 (2012)
M. Curione, S. Amato, S. Di Bona, L. Petramala, D. Cotesta, C. Letizia, Parathyroidectomy erase increased myocardial electrical vulnerability in patients with primary hyperparathyroidism. Int. J. Cardiol. 141(2), 201–202 (2010)
E. Osto, F. Fallo, M.R. Pelizzo, A. Maddalozzo, N. Sorgato, F. Corbetti, R. Montisci, G. Famoso, R. Bellu, T.F. Lüscher, S. Iliceto, F. Tona, Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 126, 1031–1039 (2012)
C. Letizia, P. Ferrari, D. Cotesta, C. Caliumi, R. Cianci, S. Cerci, L. Petramala, M. Celi, S. Minisola, E. D’Erasmo, G.F. Mazzuoli, Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J. Hum. Hypertens. 19, 901–906 (2005)
T. Ohkubo, A. Hozawa, J. Yamaguchi, M. Kikuya, K. Ohmori, M. Michimata, M. Matsubara, J. Hashimoto, H. Hoshi, T. Araki, I. Tsuji, H. Satoh, S. Hisamichi, Y. Imai, Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J. Hypertens. 20, 2183–2196 (2002)
G. Mancia, Short- and long-term blood pressure variability. Present and future. Hypertension 60, 512–517 (2012)
M. Kikuya, A. Hozawa, T. Ohokubo, I. Tsuji, M. Michimata, M. Matsubara, M. Ota, K. Nagai, T. Araki, H. Satoh, S. Ito, S. Hisamichi, Y. Imai, Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 36, 901–906 (2000)
L. Mena, S. Pintos, N.V. Queipo, J.A. Aizpúrua, G. Maestre, T. Sulbarán, A reliable index for the prognostic significance of blood pressure variability. J. Hypertens. 23, 505–511 (2005)
G. Bilo, A. Giglio, K. Styczkiewicz, G. Caldara, A. Maronati, K. Kawecka-Jaszcz, G. Mancia, G. Parati, A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall. J. Hypertens. 25, 2058–2066 (2007)
G. Parati, J.E. Ochoa, P. Salvi, C. Lombardi, G. Bilo, Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care 36, S312–S324 (2013)
G. Mancia, R. Fagard, K. Narkiewicz, J. Redón, A. Zanchetti, M. Böhm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D.E. Grobbee, T. Jaarsma, P. Kirchhof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M. Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad; Task Force Members, ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281–1357 (2013)
D.W. Cockroft, M.H. Gault, Prediction of creatinine clearance from serum creatinine. Nephron 16, 31–34 (1976)
R. Eastell, M.L. Brand i, A.G. Costa, P. D’Amour, D.M. Shoback, R.V. Thakker, Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3570–3579 (2014)
J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman, C. Marcocci, J.T. Potts, Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014)
C.A. Feldstein, M. Akopian, D. Pietrobelli, A. Olivieri, D. Garrido, Long-term effects of parathyroidectomy on hypertension prevalence and circadian blood pressure profile in primary hyperparathyroidism. Clin. Exp. Hypertens. 32(3), 154–158 (2010)
P.J. Buizert, N.M. van Schoor, S. Simsek, P. Lips, A.C. Heijboer, M. den Heijer, D.J. Deeg, E.M. Eekhoff, PTH: a new target in arteriosclerosis? J. Clin. Endocrinol. Metab. 98, E1583–E1590 (2013)
V. Heyliger, C. Tangpricha, Weber, J. Sharma, Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery 146(6), 1042–1047 (2009)
C. Gennari, R. Nami, S. Gonnelli, Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems. Miner. Electrolyte. Metab. 21(1–3), 77–81 (1995)
N.D. Vlachakis, R. Frederics, M. Velasquez, Sympathetic system function and vascular reactivity in hypercalcemic patients. Hypertension 4(3), 452–458 (1982)
M. Kosch, M. Hausberg, K. Vormbrock, K. Kisters, G. Gabriels, K.H. Rahn, M. Barenbrock, Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc. Res. 47(4), 813–818 (2000)
I.L. Nilsson, J. Åberg, J. Rastad, L. Lind, Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 126(6), 1049–1055 (1999)
T. Neunteufl, S. Heher, G. Prager, R. Katzenschlager, C. Abela, B. Niederle, T. Stefenelli, Effects of successful parathyroidectomy on altered arterial reactivity in patients with hypercalcaemia: results of a 3-year follow-up study. Clin. Endocrinol. 53(2), 229–233 (2000)
J.A. Rodriguez-Portales, C. Fardella, Primary hyperparathyroidism and hypertension: persistently abnormal pressor sensitivity in normotensive patients after surgical cure. J. Endocrinol. Invest. 17(5), 307–311 (1994)
N. Garcia de la Torre, J.A.H. Wass, H.E. Turner, Parathyroid adenomas and cardiovascular risk. Endocr. Relat. Cancer. 10(2), 309–322 (2003)
S.D. Pierdomenico, M. Di Nicola, A.L. Esposito, R. Di Mascio, E. Ballone, D. Lapenna, F. Cuccurullo, Prognostic value of different indices of blood pressure variability in hypertensive patients. Am. J. Hypertens. 22, 842–847 (2009)
S.C. Malpas, Neural influences on cardiovascular variability:possibilities and pitfalls. Am. J. Physiol. Heart Circ. Physiol. 282, H6–H20 (2002)
T.N. Thrasher, Baroreceptors and the long-term control of blood pressure. Exp. Physiol. 89, 331–335 (2004)
S.G. Massry, M. Smogorzewski, The effects of serum calcium and parathyroid hormone and the interaction between them on blood pressure in normal subjects and in patients with chronic kidney failure. J. Ren. Nutr. 15, 173–177 (2005)
G.A. Nickols, Increased cyclic amp in cultured vascular smooth muscle cells and relaxation of aortic strips by parathyroid hormone. Eur. J. Pharmacol. 116, 137–144 (1985)
G. Rashid, J. Bernheim, J. Green, S. Benchetrit, Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol. Dial. Transplant. 22, 2831–2837 (2007)
A. Virdis, F. Cetani, C. Giannarelli, C. Banti, L. Ghiadoni, E. Ambrogini, D. Carrara, A. Pinchera, S. Taddei, G. Bernini, C. Marcocci, The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism: effect of surgical treatment. J. Clin. Endocrinol. Metab. 95, 920–927 (2010)
M.R. Rubin, M.S. Maurer, D.J. McMahon, J.P. Bilezikian, S.J. Silverberg, Arterial stiffness in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90, 3326–3330 (2005)
J.L. Anderson, R.C. Vanwoerkom, B.D. Horne, T.L. Bair, H.T. May, D.L. Lappe, J.B. Muhlestein, Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am. Heart J. 162, 331–339.e2 (2011)
E. Hagstrom, E. Ingelsson, J. Sundstrom, P. Hellman, T.E. Larsson, L. Berglund, H. Melhus, C. Held, K. Michaelsson, L. Lind, J. Arnlov, Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur. J. Heart. Fail. 12, 1186–1192 (2010)
N. Levi-Marpillat, I. Macquin-Mavier, A.I. Tropeano, G. Parati, P. Maison, Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. Hypertens. Res. 37, 585–590 (2014)
G. Schillaci, G. Pucci, M. Pirro, M. Monacelli, A.M. Scarponi, M.R. Manfredelli, F. Rondelli, N. Avenia, E. Mannarino, Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis 218, 96–101 (2011)
J. Bollerslev, C. Marcocci, M. Sosa, J. Nordenström, R. Bouillon, L. Mosekilde, Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur. J. Endocrinol. 165, 851–864 (2011)
A. Persson, J. Bollerslev, T. Rosen, C.L. Mollerup, C. Franco, G.A. Isaksen, T. Ueland, S. Jansson, K. Caidahl; SIPH Study Group, Effect of surgery on cardiac structure and function in mild primary hyperparathyroidism. Clin. Endocrinol. 74, 174–10 (2011)
Acknowledgements
This research did not receive any specific grant from any funding agency in the public commercial or non-profit section.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Concistrè, A., Grillo, A., La Torre, G. et al. Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary hyperparathyroidism. Endocrine 60, 129–137 (2018). https://doi.org/10.1007/s12020-017-1362-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-017-1362-x